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Abstract Interleukin-1 (IL-1) is an important pro-inflamma-
tory cytokine that exerts its diverse biological functions by
binding to a receptor complex consisting of two transmembrane
proteins, type I IL-1 receptor (IL-1RI) and IL-1 receptor
accessory protein (IL-1RAcP). Both receptor chains are indis-
pensable for IL-1 signaling, but only IL-1RI is able to bind the
cytokine. The effects of IL-1RAcP on IL-1 binding are unclear.
This study shows that although expression of IL-1RAcP does not
alter the equilibrium dissociation constant of IL-1, it has an
effect on the non-equilibrium binding modus, most likely due to
changes in on/off rates. This defines an additional function of IL-
1RAcP: it stabilizes the active IL-1 receptor complex.
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1. Introduction
The pro-in£ammatory cytokines interleukin-1K (IL-1K) and
IL-1L, hereafter called IL-1, bind to two types of speci¢c
plasma membrane receptors of which only the type I IL-1
receptor (IL-1RI) transduces signals [1] while the type II IL-
1 receptor (IL-1RII) functions as decoy receptor without par-
ticipating in IL-1 signaling [2]. Signal transduction by IL-1RI
is only possible in concert with the IL-1 receptor accessory
protein (IL-1RAcP) [3,4] which itself does not recognize the
ligand [5] but interacts with the ligated IL-1RI on the outside
of the plasma membrane. This results in the association of the
cytoplasmic domains of IL-1RI and IL-1RAcP which are
both required for IL-1 signal transduction [6^11]. Subse-
quently the adapter protein MyD88 associates with the cyto-
plasmic domains of IL-1RI and IL-1RAcP allowing the IL-1
receptor associated protein kinase (IRAK) to translocate into
this complex [11,12]. Here IRAK becomes activated, presum-
ably by autophosphorylation, allowing subsequent signaling
events to take place [13,14].
Although the structure of IL-1 bound to IL-1RI has been
unraveled on an atomic scale recently [15,16], it remains un-
clear how IL-1RAcP recognizes the ligated receptor and
which immediate consequences this has. A ¢ve-fold increase
in IL-1 a⁄nity was reported in CHO cells stably transfected
with IL-1RI and IL-1RAcP [5], whereas no signi¢cant di¡er-
ences in IL-1 a⁄nities were observed in murine EL-4 cells
which either expressed or lacked IL-1RAcP [3,4]. This discrep-
ancy may be due to the use of di¡erent cellular models, cross-
species problems, and to the relative insensitivity of Scatchard
plot analysis in cells expressing low numbers of IL-1 recep-
tors.
As we could not observe a signi¢cant in£uence of IL-
1RAcP on the a⁄nity of IL-1 binding, we investigated the
possibility of IL-1RAcP a¡ecting the binding of IL-1 in a
di¡erent manner. Here we report (1) that in the presence of
IL-1RAcP the access of antibodies to the ligand binding site
in IL-1RI is obscured and (2) that the dissociation kinetics of
IL-1 from the IL-1RI are altered. These data suggest that IL-
1RAcP sterically protects IL-1 in the ligand binding site of IL-
1RI. It can be hypothesized that by forming a ‘cage’ for IL-1
IL-1RAcP slows the dissociation kinetic of IL-1 from the
receptor complex.
2. Materials and methods
2.1. Cell culture
The murine T cell lines EL-4 6.1 (kind gift of R. McDonald, Lau-
sanne, Switzerland) and EL-4 D6/76 (kind gift of W. Falk, Regen-
burg, Germany) were maintained at 37‡C, 5% CO2 in RPMI 1640
supplemented with 5% (v/v) fetal calf serum, 1 mmol/l pyruvate, non-
essential amino acids (minimum essential medium) and 2 mmol/l L-
glutamine (Gibco). The cells were passaged every 2^3 days to main-
tain a cell density of 105^106 cells/ml.
2.2. Scatchard analysis
IL-1K (108 units/mg, kindly provided by John Sims, Immunex, Se-
attle, WA, USA) was labeled with 125I using the chloramine T method
as described elsewhere [17]. To determine the a⁄nity of IL-1 receptor
complexes 5U106 cells in 150 Wl medium additionally supplemented
with 0.1% (w/v) sodium azide were pre-incubated for 30 min on ice
with or without 100-fold molar excess of unlabeled IL-1. To each vial
[125I]IL-1K was added in a concentration range between 5 and 3840
pmol/l. After 3 h of incubation on ice the cell suspension was layered
on top of a cushion consisting of silicon oil (AR20/AR200 1:1, Wack-
er Chemikalien, Munich, Germany). The tubes were centrifuged (2
min, 5000 rpm, 4‡C), decapitated and both parts (upper compart-
ment: free IL-1; lower compartment: cells with bound IL-1) were
counted using a gamma counter.
The a⁄nity of the receptor complexes and the number of binding
sites were calculated using the equation
X
ligandfree 
n
Kdiss
3
X
Kdiss
with X= c(ligandbound)/c(cells) and n = number of binding sites [18]. By
plotting n/c(ligandfree) versus n the dissociation constant Kdiss is ob-
tained by the negative slope and the number of binding sites by the
abscissa intercept.
2.3. Competition studies with unlabeled IL-1 and IL-1RI antibodies
(FACS analysis)
106 cells were washed twice in PBS/1% (v/v) FCS/0.1% (w/v) NaN3
and pre-incubated in 200 Wl of PBS with 280 ng/ml IL-1K or IL-1L
(rhIL-1K : s 108 units/mg, Immunex; rhIL-1L, 5^10U108 units/mg,
DompeŁ, L’Aquila, Italy) for 10 min at room temperature. The cells
were washed again and resuspended in 20 Wl Endobulin (Immuno,
Heidelberg, Germany), 50 Wl PBS/FCS/NaN3 and 10 Wl of ¢rst anti-
body (mIL-1RI antibodies 35F5 or 12A6, Pharmingen, Hamburg,
Germany, ¢nal concentration 0^5 Wg/ml). After incubation for 15
min at room temperature followed by 20 min on ice the cells were
washed twice, resuspended in 100 Wl DTAF-conjugated anti-rat IgG
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antibody (Dianova, Hamburg, Germany, 1:200 in PBS/FCS/NaN3),
incubated on ice for 30 min, and ¢nally washed twice with PBS/FCS/
NaN3. The £uorescence intensity of the samples was measured using a
£uorescence activated cell scanner (FACScan, Becton Dickinson, Hei-
delberg, Germany).
2.4. Competition studies with radiolabeled IL-1 and IL-1RI antibodies
2.5U106 cells in 150 Wl medium additionally supplemented with
0.1% (w/v) sodium azide were incubated on ice with 5 ng/ml
[125I]IL-1K for 1.5 h. Cells were washed twice by centrifugation with
medium/NaN3 and incubated with the neutralizing mIL-1RI antibody
35F5 (Pharmingen, ¢nal concentrations 0^22 nmol/l) for 1.5 h on ice.
The cell suspensions were centrifuged through silicone oil as described
in Section 2.2 and the IL-1 bound was measured by gamma counting.
2.5. Competition studies with radiolabeled and unlabeled IL-1
5U106cells were incubated with 10 ng/ml [125I]IL-1K for 30 min on
ice. Then di¡erent amounts of unlabeled IL-1K or unlabeled IL-1L
(¢nal concentrations 0^188 nmol/l) were added and the samples were
incubated for an additional 60 min. Separation of free and bound IL-
1 and detection was performed as described above.
3. Results
3.1. IL-1RAcP has no e¡ect on IL-1 a⁄nity to IL-1RI
The e¡ect of IL-1RAcP expression on IL-1 a⁄nity was
analyzed in two sublines of the murine T cell line EL-4. EL-
4 6.1 is a frequently employed IL-1-responsive cell line ex-
pressing both IL-1RI and IL-1RAcP [19] whereas EL-4 D6/
76 was initially identi¢ed through its inability to respond to
IL-1 [20]. This non-responsiveness is due to the lack of IL-
1RAcP expression and can be restored by transfection with
expression plasmids encoding this protein [3,4].
Both cell lines are known to express relatively high numbers
of IL-1RI, whereas IL-1RII is not detectable at the protein
level and only in trace amounts via RT-PCR [19].
In order to compare the IL-1 a⁄nity of these two sublines
they were incubated with di¡erent concentrations of [125I]IL-
1K until equilibrium was reached (3 h on ice). The number of
IL-1 binding sites and the binding a⁄nity was determined via
Scatchard plot analysis (Fig. 1). Both cell lines expressed sim-
ilar numbers of IL-1 binding sites (1167 for EL-4 6.1 and 1691
for EL-4 D6/76). The dissociation constant for IL-1 was al-
most identical in these two sublines (1.6 nmol/l for EL-4 6.1
and 1.8 nmol/l for EL-4 D6/76). In equilibrium the two cell
lines showed no di¡erence in IL-1 a⁄nity, although EL-4 D6/
76 does not express IL-1RAcP. Thus, in the EL-4 system IL-
1RAcP expression had no e¡ect on the a⁄nity of IL-1 binding
by IL-1RI.
3.2. IL-1RAcP protects bound IL-1 from competition with
neutralizing antibodies
Competition studies were utilized to study the in£uence of
IL-1RAcP on IL-1 binding in more detail. EL-4 6.1 and EL-4
D6/76 were pre-incubated with IL-1K or IL-1L and after re-
moval of unbound IL-1 incubated with di¡erent concentra-
tions of either a neutralizing monoclonal antibody (mAb)
against IL-1RI (35F5) or a non-neutralizing mAb (12A6)
for a short period of time (competition). While 35F5 is com-
peting with IL-1 for the IL-1RI binding site, binding of 12A6
is independent of IL-1 and was used as a control to show that
the level of surface expression of IL-1RI was not altered dur-
ing the experiment.
The competition was quanti¢ed either by measuring the
amount of bound mAb by FACS analysis (Fig. 2) or by
determining the amount of bound, radiolabeled IL-1 after
competition with the mAbs in binding assays (Fig. 3).
Under these experimental conditions (non-equilibrium)
binding of the neutralizing mAb 35F5 was in£uenced by IL-
1RAcP expression: when EL-4 6.1 (IL-1RAcP-positive) were
pre-incubated with IL-1K or IL-1L, the antibody could not be
detected on the cell surface, whereas the non-neutralizing con-
trol antibody 12A6 bound freely in a concentration-dependent
manner (Fig. 2A,B). In this experimental setting the IL-
1RAcP-negative cell line EL-4 D6/76 behaved di¡erently.
Both antibodies, the neutralizing and the non-neutralizing
one, bound concentration-dependently (Fig. 2C,D), demon-
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Fig. 1. E¡ect of IL-1RAcP expression on IL-1 a⁄nity (Scatchard
analysis). EL-4 6.1 (IL-1RAcP-positive, panel A) and EL-4 D6/76
cells (IL-1RAcP-negative, panel B) were incubated with di¡erent
concentrations of [125I]IL-1K. Non-speci¢c binding was determined
in the presence of a 100-fold excess of unlabeled IL-1. The IL-1
bound was determined using a gamma counter. Dissociation con-
stants (Kdiss) and numbers of binding places (n) were calculated by
Scatchard analysis.
Fig. 2. Competition of IL-1 and antibody binding (FACS analysis).
EL-4 6.1 (A and B) and EL-4 D6/76 cells (C and D) were pre-incu-
bated with 280 ng/ml IL-1K (A and C) or IL-1L (B and D). For
competition of IL-1 binding the cells were incubated either with the
neutralizing IL-1RI antibody 35F5 or with the non-neutralizing IL-
1RI antibody 12A6 (control). Binding of the IL-1RI antibodies was
detected with DTAF-labeled secondary antibody.
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strating that competition of the antibodies with IL-1 for the
ligand binding site in IL-1RI was only possible in the absence
of IL-1RAcP.
Determination of bound IL-1 yielded the same result. In
EL-4 6.1 the amount of bound IL-1 was not in£uenced by
incubation with 35F5, whereas in EL-4D6/76 mAb 35F5 and
IL-1 were competing: the higher the concentration of 35F5 in
the competition experiment, the less IL-1 was found on the
cell surface (Fig. 3). Thus, although IL-1RAcP did not in£u-
ence the a⁄nity of the IL-1 receptor complex in equilibrium,
it altered the ‘accessibility’ of the bound cytokine.
3.3. IL-1RAcP prevents competition of free IL-1 with IL-1
bound to IL-1RI
The stability of IL-1 binding in the presence or absence of
IL-1RAcP was further analyzed by studying the exchange of
bound ligand. EL-4 6.1 and EL-4 D6/76 were pre-incubated
with radiolabeled IL-1K for 30 min followed by 60 min incu-
bation with di¡erent concentrations of unlabeled IL-1K or
unlabeled IL-1L.
Only a relatively minor fraction of the radiolabeled cyto-
kine was exchanged against unlabeled IL-1 in the IL-1RAcP
positive cell line EL-4 6.1, while a much bigger fraction of the
[125I]IL-1K was displaced by unlabeled IL-1 in EL-4 D6/76 at
even lower concentrations of competitor. Similar results were
obtained for both IL-1K (data not shown) or IL-1L as com-
petitor (Fig. 4).
4. Discussion
IL-1RAcP immediately attracted the attention of the scien-
ti¢c community after its initial description in 1995 [5], and it
has become quite clear that IL-1RAcP is required as a co-
receptor for IL-1 signaling. Although IL-1RAcP is a member
of the growing IL-1 receptor family and shows signi¢cant
homology to IL-1RI and IL-1RII, it is unable to bind IL-1
itself. IL-1RAcP can be detected in the receptor complex by
chemical crosslinking [5] or co-immunoprecipitation [9] only
upon binding of IL-1K or IL-1L, but not IL-1Ra to IL-1RI.
This suggests that IL-1RI and IL-1RAcP are not constitu-
tively associated but form a heterodimeric complex in the
presence of the biologically active IL-1 molecules. This lig-
and-mediated heterodimerization is a minimal working model
and nothing is currently known of the stoichiometry of this
complex. Interestingly, the intracellular domains do not seem
to be required for the ligand-mediated association and heter-
odimerization, as a truncated form of IL-1RAcP can be co-
precipitated with IL-1RI in the presence of IL-1 [9]. However,
it is well established that the cytoplasmic domains of both IL-
1RI and IL-1RAcP are indispensable for initiation of IL-1
signal transduction [6,9,11].
Recently, the structures of IL-1L and IL-1Ra bound to
soluble IL-1RI were resolved by X-ray crystallography, allow-
ing further insights into the interaction of ligand and receptor
[15,16]. These data suggest that IL-1L and IL-1Ra are recog-
nized and bound by the two N-terminally situated immuno-
globulin-like domains of IL-1RI which seem to be rather rig-
idly connected. Upon binding by these domains only IL-1L is
able to interact (via charged residues) with the third Ig-like
domain leading to a conformational change, while IL-1Ra is
unable to cause such a change in the overall structure of the
ligated receptor. As no co-crystallization of ligated IL-1RI
and IL-1RAcP has been reported, it remains elusive whether
IL-1RAcP recognizes epitopes of both receptor and ligand
which have been exposed or created after the conformational
change or whether only bound IL-1 is seen. One hint comes
from the observation that IL-1Ra can be changed into an
agonist by exchanging only one amino acid (residue Lys145
in IL-1Ra into Asp in IL-1L) [21]. As this Asp145 does not
seem to be involved in receptor interaction, it was speculated
that it may be involved in interaction with IL-1RAcP [16].
This form of molecular interaction between ligated IL-1RI
and co-receptor points to at least two possible functions for
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Fig. 3. Competition of [125I]IL-1K and antibody binding. EL-4 6.1
and EL-4 D6/76 cells were pre-incubated with 5 ng/ml [125I]IL-1K.
For competition of IL-1 binding the cells were incubated with the
neutralizing IL-1RI antibody 35F5. The IL-1 bound after the com-
petition was measured using a gamma counter.
Fig. 4. Competition of 125I-labeled IL-1K and unlabeled IL-1L. EL-4
6.1 and EL-4 D6/76 cells were pre-incubated with 10 ng/ml [125I]IL-
1K. For competition of IL-1 binding the cells were incubated with
unlabeled IL-1L for 60 min on ice. The amount of bound [125I]IL-
1K was measured by gamma counting.
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IL-1RAcP in the process of IL-1 binding. Firstly it could
enhance the a⁄nity of the receptor complex, and secondly it
could a¡ect ligand receptor interaction by stabilizing the com-
plex.
The aim of this study was to characterize the function of
IL-1RAcP in IL-1 binding to IL-1RI in EL-4 cells. In contrast
to the original description in which an increase in IL-1 a⁄nity
to its receptor by IL-1RAcP was reported [5], no evidence for
di¡erences in IL-1 a⁄nities was seen in EL-4 cells in the
absence or presence of IL-1RAcP. In stably transfected
CHO cells expressing 7U105 receptors, IL-1RI is a binding
site with a KD of 1.2 nM, whereas upon co-expression of IL-
1RI and IL-1RAcP this a⁄nity increases about ¢ve-fold to
0.25 nM and thus constitutes the high a⁄nity IL-1 binding
site. This model is similar to the situation found in other
cytokine receptor families, where the ligand binding site has
a rather moderate or low a⁄nity for the ligand which is
changed into a high a⁄nity site by a co-receptor chain which
itself does not necessarily have to bind the ligand, e.g. in the
IL-2 system. In EL-4 cells a signi¢cant change in KD values in
EL-4 cells was achieved neither by transfecting the murine
EL-4 cell line D6/76 with IL-1RAcP [3,4] nor by comparing
the a⁄nities of IL-1RAcP-positive and -negative EL-4 cell
lines (Fig. 1). In these Scatchard plot analyses only one type
of binding site was measured and no evidence was found for
high and low a⁄nity binding sites for IL-1 on EL-4 cells in
the absence or presence of IL-1RAcP. Therefore it must be
concluded that in EL-4 cells IL-1RAcP does not contribute
signi¢cantly to the equilibrium binding of IL-1 to IL-1RI and
does not a¡ect binding a⁄nities.
As we hypothesized that IL-1RAcP may have a di¡erent
function in the receptor complex we investigated the second
conceivable function of IL-1RAcP: the stabilizing function.
The interpretation of the three-dimensional structure suggests
that by associating with the ligated receptor IL-1RAcP may
cover IL-1 in its binding pocket and thus stabilize the inter-
action between IL-1RI and IL-1 by locking IL-1 in this micro-
environment. This would deny a normal o¡ dissociation of the
ligand from the receptor and would imply that the ligand
binding site is di¡erently accessible in absence or presence
of IL-1RAcP. Here we demonstrated that this is indeed the
case. Firstly, we employed the neutralizing anti-murine IL-
1RI mAb 35F5 which binds to the ligand binding site in IL-
1RI and competes with IL-1 for the binding site. In non-equi-
librium studies release of pre-bound IL-1K or IL-1L by the
mAb was only possible in the EL-4 D6/76 cells, which lack
IL-1RAcP, but not in EL-4 6.1 cells, which posses IL-1RAcP.
Thus the accessibility of the neutralizing mAb to its epitope
was denied by IL-1RAcP, most likely by steric hindrance.
This was true not only for competition with the neutralizing
antibody but also with IL-1K or IL-1L. Again a much higher
exchange of pre-bound (radiolabeled) IL-1 with free IL-1 was
possible in the cells lacking IL-1RAcP. This e¡ect can only be
explained by a protective function of IL-1RAcP. Both set of
results prove that the access to the ligand binding site is ob-
scured by IL-1RAcP and that dissociation of pre-bound IL-1
out of the receptor complex is a¡ected negatively by IL-
1RAcP which possibly creates a micro-environment favoring
re-association of the ligand to the receptor binding site rather
than dissociation out of the complex. This e¡ect would pro-
long o¡ rates and change the non-equilibrium binding of IL-1
to its receptor, rather than increasing the equilibrium a⁄nity.
Thus we propose that IL-1RAcP functions as a stabilizer of
the IL-1 receptor signaling complex in EL-4 cells. These two
molecular mechanisms are not mutually exclusive and it is
possible that in other cellular systems IL-1RAcP functions
in both directions by moderately increasing the a⁄nity of
the receptor for IL-1 and by stabilizing the IL-1 receptor
signaling complex.
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